Published in Alzheimers Dement on January 01, 2010
Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol (2014) 0.83
Treatment of frontotemporal dementia. Curr Treat Options Neurol (2014) 0.79
Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: Report of three cases. Surg Neurol Int (2014) 0.76
Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem (2016) 0.75
Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag (2016) 0.75
A case of atypical progressive supranuclear palsy. Clin Interv Aging (2013) 0.75
Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses. Z Gerontol Geriatr (2012) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol (2011) 3.01
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int (2013) 2.22
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord (2008) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol (2008) 1.79
DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med (2009) 1.78
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol (2011) 1.62
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet (2009) 1.59
Kick and rush: paradoxical kinesia in Parkinson disease. Neurology (2008) 1.59
Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol (2009) 1.58
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet (2006) 1.56
UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol (2004) 1.54
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology (2012) 1.51
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord (2013) 1.48
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol (2011) 1.45
Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet (2002) 1.44
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Transcranial sonography in movement disorders. Lancet Neurol (2008) 1.44
Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem (2009) 1.42
The effect of increased maximum power output on perioperative and early postoperative outcome in photoselective vaporization of the prostate. Lasers Surg Med (2012) 1.41
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology (2012) 1.41
Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. Arq Neuropsiquiatr (2011) 1.40
E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene (2004) 1.40
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol (2007) 1.37
The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet (2003) 1.36
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol (2007) 1.34
Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol (2002) 1.33
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging (2014) 1.32
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.29
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord (2012) 1.28
[11C]PIB binding in Parkinson's disease dementia. Neuroimage (2007) 1.24
In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord (2005) 1.23
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat (2004) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem (2011) 1.19
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18